Specifically, some of the DE responding miRNAs (miR-199a-3p, miR-199a-5p, miR-29b-3p, and miR-23b-3p), whose levels were modulated by the CLA treatment, are known to be dysregulated and of clinical interest in MS. This evidence concerns the gene SELPLG and myeloid sarcoma.